Pancreatic cancer is one of the most difficult cancers to treat, with an overall five-year survival rate of 13%, according to the American Cancer Society, stretching from 3% for metastatic (Stage 4) to 44% for localized (Stages 1 and 2).
Dismal odds such as these explain the enthusiastic response of investors when Revolution Medicine (NASDAQ: RVMD), a developer of RAS-addicted cancer therapies, an...
The biotech sector is experiencing a moment of high-stakes validation and speculation, driven by two parallel narratives: breakthrough oncology data and a resurgent IPO market. Revolution Medicines’ daraxonrasib results are undeniably impressive—doubling survival in a disease with historically dismal outcomes—but the market’s reaction raises questions about the durability of such gains. The 54% stock surge reflects not just the data’s strength but also the desperation for effective pancreatic ca...